BioPharmSignal logoBioPharmSignal

Biotech News

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals (TARS)Tarsus PharmaceuticalsConference / presentation

IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: William Blair 46 th Annual Growth Stock Conference on Tuesday, June 2 nd, at 8:00 a.m. PT / 11:00 a.m.

Related news

TARSTarsus Pharmaceuticals2026-03-23 12:30 EST

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

OCSOculis2026-07-02 08:00 EST

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

PRQRProQR Therapeutics2026-05-11 12:00 EST

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform

OKYOOKYO Pharma2026-07-27 11:00 EST

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

BLTEBelite Bio2026-07-15 12:00 EST

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

BLTEBelite Bio2026-06-02 12:00 EST

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

IRIXIRIDEX2026-06-09 20:05 EST

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference

OCSOculis2026-06-08 19:25 EST

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

HROWHarrow, Inc.2026-05-27 11:00 EST

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

View all latest news

Tarsus Pharmaceuticals

Eye-Care Therapeutics Tarsus Pharmaceuticals develops and commercializes medicines that target underlying causes of eye disease, using the antiparasitic agent lotilaner across multiple formulations and indications. XDEMVY XDEMVY is an ophthalmic lotilaner solution approved for Demodex blepharitis. It eradicates Demodex mites through a...

Recent company news

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

TARSTarsus Pharmaceuticals2026-08-06 11:02 EST

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

TARSTarsus Pharmaceuticals2026-08-06 11:01 EST

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

TARSTarsus Pharmaceuticals2026-08-06 00:03 EST

Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

TARSTarsus Pharmaceuticals2026-07-13 20:05 EST

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Stock data

Close
65.33 USD
Market cap
2.47B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States